Acepodia

Acepodia is a clinical-stage biotechnology company leveraging its proprietary Antibody-Cell Conjugation (ACC) platform technology to develop first-in-class cell therapies addressing unmet needs in cancer care. The company utilizes its ACC technology to link tumor-targeting antibodies with its proprietary immune cells, such as gamma delta T cells and off-the-shelf natural killer (NK) cells, to create novel Antibody-Cell Effector (ACE) therapies, which enhance binding affinity to tumors expressing low levels of tumor antigens. Comprised of experienced leaders and scientific experts, Acepodia is committed to advancing its robust pipeline of off-the-shelf ACE therapies, with the potential to deliver innovative, effective, and affordable cell therapies to a broad patient population across various solid tumors and hematological malignancies.